Enovis Corp Stock Price, News & Analysis

Enovis Corporation announced the FDA's approval of the STAR Patient Specific Instrumentation (STAR PSI System) for total ankle replacements, marking a significant advancement for surgeons and patients. This system allows for personalized pre-operative planning, integrating a 3D visualization of each patient's ankle joint, which enhances surgical accuracy and efficiency. The STAR PSI System is set to enter Early Product Surveillance in December 2022, with a full launch anticipated by March 2023. This product joins Enovis' expanding portfolio aimed at improving patient outcomes.

Enovis Corporation (NYSE: ENOV) has launched the DynaNail Helix™, enhancing dynamic compression in foot and ankle fusion procedures. This innovative product leverages proven NiTiNOL technology to provide sustained compression, which traditional screws lack. The DynaNail Helix is designed for easy insertion, minimizes the need for manual adjustment, and allows up to 4mm of post-operative compression to adapt to bone resorption. As part of Enovis' comprehensive suite, it aims to improve patient recovery and outcomes, reinforcing the company's commitment to advanced medical technologies.

Enovis Corporation (NYSE: ENOV) has been awarded the Industry Innovation Award at the American Academy of Hip and Knee Surgeons (AAHKS) Annual Meeting for its ARVIS Augmented Reality Surgical Guidance System. This groundbreaking AR technology allows orthopedic surgeons to visualize precision guidance during hip and knee surgeries. Unlike large robotic systems, ARVIS is FDA-cleared and designed for easy adoption in surgical centers, providing more patients access to advanced surgical options. Enovis aims to enhance patient outcomes with ongoing innovations.

Enovis Corporation (NYSE: ENOV) reported third-quarter 2022 sales of $384 million, a 7% increase year-over-year, driven by double-digit growth in its Reconstructive segment. However, the company faced a net loss of $(66) million or $(1.22) per diluted share. Adjusted earnings per share improved by 34% to $0.59, with adjusted EBITDA at $57 million, representing 14.9% of sales. Enovis launched innovative products, including the EMPOWR 3D Knee™ and connected bracing solutions. The company anticipates total sales growth of approximately 10% for 2022.

Enovis Corporation (NYSE: ENOV) has announced participation in two investor conferences this November. CFO Chris Hix and incoming CFO Ben Berry will speak at the Credit Suisse 31^st Annual Healthcare Conference on November 8 in Rancho Palos Verdes, CA. Later, on November 29, CEO Matt Trerotola and Ben Berry will participate in the Evercore ISI 5^th Annual HEALTHCONx virtual conference. Enovis specializes in medical technology and is committed to improving patient outcomes through innovative solutions.

Enovis Corporation (NYSE: ENOV) will host an investor conference call and live webcast on November 2, 2022, at 8:00 AM ET to discuss its Q3 2022 financial results. An earnings press release will precede the call. Investors can access the live webcast through the Enovis website, and for participation, U.S. callers can dial (800) 715-9871, while international callers should use (646) 307-1963 with conference ID 1914045. A replay will also be available later on the website. Enovis focuses on innovative medical solutions for improved patient outcomes.

Enovis Corporation (NYSE: ENOV) is set to showcase its expanding foot and ankle portfolio at the AOFAS annual meeting in Quebec City from September 14-17, 2022. Highlighting recent FDA-cleared products like DynaClip Delta™ and DynaClip Quattro™, the company aims to enhance patient outcomes through innovative solutions. Enovis will also present its Future of STAR® Ankle and offer hands-on workshops. The company remains committed to driving technological advancements in the orthopedic sector.

Enovis Corporation (NYSE: ENOV) has announced participation in two key investor conferences in September 2022. The Wells Fargo Healthcare Conference will be held on September 7 in Boston, featuring CEO Matt Trerotola and CFO Ben Berry. Following this, the Baird Global Healthcare Conference is on September 14 in New York, with Trerotola and outgoing CFO Chris Hix attending. Enovis focuses on medical technology innovations that improve patient outcomes and efficiency in orthopedics.

Enovis Corporation (NYSE: ENOV) reported second quarter 2022 sales of $395 million, marking an 11% increase. Operating income stood at $6 million, with adjusted EBITDA rising 11% to $56 million. The net income was $121 million, equating to $2.21 per diluted share, while adjusted earnings per share surged 44% to $0.59. The company updated its full-year adjusted EBITDA outlook to $235-255 million, adjusting its EPS guidance to $2.15-$2.35 due to currency pressures and a tax benefit. Enovis recently acquired Insight Medical Systems and 360 Med Care, expanding its market reach and innovation.